With five novel oral therapies in late-stage development, there could soon be a wide range of treatment options for relapsing–remitting multiple sclerosis, but better biomarkers are needed to more ...

Based on promising results from the Phase 1a study including sustained disability improvements among progressive MS patients, the Phase 1b study will assess clinical outcomes including measures of ...

The role of imaging in diagnosing progressive multiple sclerosis (MS) and in assessing prognosis is the subject of a new review. MRI is central in the diagnostic workup of patients suspected of having ...

Rebecca Spain, M.D., M.S.P.H., is lead author on a new randomized controlled clinical trial testing the over-the-counter supplement lipoic acid in treating progressive forms of multiple sclerosis. The ...

AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...

– Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) ...

Secondary progressive multiple sclerosis (SPMS) usually develops after years of relapsing-remitting multiple sclerosis (RRMS) and leads to steadily worsening symptoms and disability over time. SPMS ...